Buy & Sell Digital Realty Trust, Inc. (DLR) – Digital Realty Trust, Inc. Price Today
Aura AI Summary
Key Stats
- $64.25BMarket Cap
- Real EstateSector
- -11.34%3M Drawdown
- $81.77BEnterprise Value
- 2.67%Dividend Yield
- 93% Buy | 7% SellTrading Activity
- 92 daysTypical Hold Time
Digital Realty Trust, Inc. (DLR) is currently valued at a market capitalization of $64.25B, with an enterprise value of $81.77B. Over the past 52 weeks, Digital Realty Trust, Inc. has traded between a low of $147.93 and a high of $203.91, highlighting its annual price range. Over the past three months, Digital Realty Trust, Inc. has recorded a drawdown of -11.34%, reflecting recent price volatility. Digital Realty Trust, Inc. offers a dividend yield of 2.67%, with the most recent dividend of $1.22 paid on 13 Mar 26. On average, investors hold Digital Realty Trust, Inc. for approximately 92 days, indicating typical investor behavior on the platform.
About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Most Recent News
US government buys 10% stake in mining firms, signaling a new strategic investment trend.
In early 2026, the US government began acquiring stakes in American mining companies, including a 10% share in USA Rare Earth to support critical mineral projects. This move follows similar investments in Lithium Americas and Trilogy Metals, which sa...
FDA approves Sanofi's Tzield as first disease-modifying therapy for stage 3 type 1 diabetes in children.
The FDA has granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). This is the first disease-modifying therapy aimed at delaying the decline of insulin produc...
FDA approves Sanofi's Tzield as first disease-modifying therapy for newly diagnosed stage 3 type 1 diabetes in children.
The FDA granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). Tzield slows the decline of the body's insulin production by targeting the autoimmune process c...